Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Dynavax Technologies Corporation is placed fifth among them.

Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company specializing in innovative vaccines, is gaining momentum with strong financial results and pipeline progress. The company’s lead product, HEPLISAV-B, continues to drive growth, while new vaccine candidates in shingles, influenza, and Lyme disease highlight its expanding focus.

In Q2 2025, Dynavax Technologies Corporation (NASDAQ:DVAX) reported record net product revenue of $92 million for HEPLISAV-B, up 31% year-over-year. The business also raised its full-year revenue outlook to between $315 million and $325 million, which reflected strong demand for the hepatitis B vaccine. Efforts are underway to expand its use, including a retrospective study in adults on hemodialysis to support a supplemental FDA filing.

The business’s most closely watched program is its shingles vaccine candidate, Z-1018, now in a Phase 1/2 trial with top-line results expected in August 2025. The company believes Z-1018 could emerge as a best-in-class option in a multi-billion-dollar market currently dominated by limited players.

Beyond shingles, Dynavax is advancing its pandemic influenza program, testing its CpG 1018 adjuvant in an H5N1 vaccine, with key data anticipated in 2026. The company is also targeting Lyme disease, developing a multivalent protein subunit vaccine with CpG 1018, currently in IND-enabling studies and expected to enter clinical trials in 2027.

Dynavax Technologies Corporation (NASDAQ:DVAX) will further outline its growth strategy at the 2025 Wells Fargo Healthcare Conference on September 3, where executives are expected to discuss both commercial momentum and the expanding vaccine pipeline.

While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.